Underdog Pharmaceuticals Named A Lighthouse Investment by Kizoo Technology Ventures


Kizoo Technology Capital GmbH has recently announced a $362M commitment to invest in rejuvenation biotechnology. If you haven’t seen the compelling write-up in BioWorld Today, please take a moment to read it here.

Underdog was delighted to be referenced therein as one of Kizoo’s “lighthouse” investments. Kizoo’s continued support in our Series A positions us to become a leader in the rejuvenation biotechnology revolution; their commitment to that industry is unparalleled and will transform the way treat age related disease. Thank you, Michael Greve, for this commitment!

Mike and Oki

Share on facebook
Share on twitter
Share on reddit
Share on linkedin
Share on whatsapp
Share on email

Underdog News:

Kizoo Portfolio Company Underdog Closes $10M Financing Round

Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has closed a $10 million round of capital. Kizoo led the company’s Series Seed II round, which saw participation from both existing and new investors.

Underdog was recently awarded the Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP). This will enable faster patient access to its groundbreaking treatment for the prevention of heart attacks and stroke. The company expects to begin clinical trials in 2023.

Read More »

7-Ketocholesterol in disease and aging

Scientists from Underdog Pharmaceuticals, in conjunction with Professor Jay Jerome of Vanderbilt University Medical Center, have published an article in the journal Redox Biology, covering the role of the toxic biomolecule 7-ketocholesterol, especially in the

Read More »

© 2021 Underdog Pharmaceuticals – ALL RIGHTS RESERVED

Site developed by Moonburn.com

© 2022 Underdog Pharmaceuticals – ALL RIGHTS RESERVED

Site developed by Moonburn.com